The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com.
The DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
The DSR® therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe.
alfapump DSR® – combines Sequana Medical’s breakthrough DSR therapy with its alfapump®
DSR® – potential new treatment for diuretic-resistant fluid overload due to heart failure
Heart failure and diuretic-resistant fluid overload
alfapump® – new ascites treatment for more quality of life
Recovered quality of life with the alfapump® system
Ascites and NASH related Cirrhosis
The alfapump® for the management of fluid overload
POSEIDON study interim results – November 2020
RED DESERT study interim results – October 2020
alfapump DSR® therapy in heart failure
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.